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In order to address JJ-TRIALS goals of: a) improving
behavioral health services for youth with substance use
problems; and b) advancing the investigation of imple-
mentation efforts in the field of behavioral health, the
JJ-TRIALS Workgroup on Evidence-Based Practices
(EPA) was first charged with defining quality indicators
for practices and programs. We limited that effort to
programs, practices, and instruments relevant to the
steps in the Behavioral Services Cascade (Screening,
Referral and Linkage, Assessment, Prevention and Psy-
chosocial Treatment) for five identified clinical problem
areas (Substance use, Mood disorder, ADHD, Trauma
exposure, HIV risk). Problem areas were selected as
those of moderate prevalence among adolescents in
community justice systems with problem substance use.
Quality indicators were consistent with the AACAP
Practice Parameters Clinical Standard, as reflecting
either “rigorous empirical evidence” or “overwhelming
clinical consensus” (American Academy of Child and
Adolescent Psychiatry, 2013). In a series of directed lit-
erature reviews, we catalogued evidence-based programs
and instruments addressing these problem areas that
had been identified as most strongly supported by exist-
ing systematic reviews (e.g., SAMHSA, 2011) and then
categorized them into tiers, based on their applicability
for JJ-TRIALS efforts (e.g., number of TRIALS problem
areas addressed, administration format, delivery setting,
inclusion of family collaterals). These reviews identified
18 psychometrically sound screening instruments (3
tiers), 16 sound assessment instruments (4 tiers), 43 EB
prevention programs (3 tiers), and 39 EB treatment pro-
grams (3 tiers). While the evidence base regarding
programs that focus on cross-system linkage (e.g., from
screening in a probation setting, with a subsequent
referral to a behavioral health provider) is less estab-
lished, EPA was able to designate three tiers of such
programs, defined both by their soundness and their
applicability to juvenile justice community settings. As a
second set of quality indicators, we considered core con-
tent components (that may cut across particular instru-
ments or programs). For assessment, these included
eight elements essential for clinical treatment planning
for adolescents (e.g., family relationships, readiness for
change: American Society of Addiction Medicine, 2013).
For treatment programs, these included treatment mod-
alities identified as effectively addressing one or another
of the TRIALS problem areas (e.g., CBT; Chorpita, et
al., 2011). A final quality indicator for assessment and
treatment considered procedural elements (that relate to
how an instrument or program is used by a service pro-
vider), such as manualization, staff training, and fidelity
monitoring (e.g., Brannigan, 2004; Howell & Lipsey,
2012). EPA workgroup products will be incorporated
into future JJ-TRIALS training efforts; they will be used
to generate menus of high-quality instrument and pro-
gram options to help juvenile justice partners and the
behavioral health agencies with which they collaborate
to set implementation goals for participation in
JJ-TRIALS.
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